We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
HWH | HWH International Inc | 1.85 | 0.57 | 44.53% | 649,573 |
PEGY | Pineapple Energy Inc | 0.06295 | 0.01715 | 37.45% | 20,737,465 |
IBRX | ImmunityBio Inc | 6.56 | 1.62 | 32.79% | 996,880 |
NUWE | Newellis Inc | 0.4138 | 0.0798 | 23.89% | 2,123,311 |
AGBA | AGBA Group Holding Ltd | 3.02 | 0.52 | 20.80% | 1,576,387 |
HIBB | Hibbett Inc | 85.02 | 12.53 | 17.29% | 1,455 |
OPRT | Oportun Financial Corporation | 2.61 | 0.36 | 16.00% | 7,135 |
GTIM | Good Times Restaurants Inc | 2.96 | 0.39 | 15.18% | 1 |
AIH | Aesthetic Medical International Holdings Group Ltd | 0.425 | 0.0547 | 14.77% | 1,158 |
ISPC | iSpecimen Inc | 0.388 | 0.048 | 14.12% | 10,867 |
RWOD | Redwoods Acquisition Corporation | 9.94 | 1.10 | 12.38% | 5,267 |
ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
Hibbett, Inc. (“Hibbett”) (Nasdaq:HIBB), an athletic-inspired fashion retailer, today announced a definitive agreement in which JD Sports Fashion plc (“JD Sports”) (LSE:JD) will acquire all outstanding shares of Hibbett for $87.50 per share in cash, representing an aggregate enterprise value of approximately $1.1 billion.
FY 2023: 5-year-record Revenues $26.6 million; EBITDA Growth of 2350%Q4 2023: Revenues $5.7 million; EBITDA $1.1 million; Non-GAAP EPS of $0.15 TEL AVIV, Israel , April 22, 2024 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today reported results for the twelve months and fourth quarter, ended December 31, 2023.
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place from May 7-11, 2024, in Baltimore, MD. The oral presentation will take place on May 10, 2024 in the Targeted Gene and Cell Therapy session, co-chaired by Adicet Bio’s Chief Scientific Officer, ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 66,087.85 | -770.10 | -1.15% | 1.3T | 3,490,758,953 |
ETH | Ethereum | 3,168.79 | -33.27 | -1.04% | 380.39B | 1,585,224,858 |
USDT | Tether USD | 1.00 | 0.00 | 0.00% | 97.84B | 401,278,863 |
BNB | Binance Coin | 605.33 | 0.225913 | 0.04% | 95.64B | 290,890,361 |
SOL | Solana | 153.90 | -3.11 | -1.98% | 67.71B | 1,058,557,339 |
STETH | stETH | 3,154.56 | -45.90 | -1.43% | 31.02B | 3,187,444 |
XRP | Ripple | 0.5444 | -0.0122 | -2.19% | 29.71B | 431,307,618 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 1,068,264,177 |
DOGE | Dogecoin | 0.15815 | -0.00308 | -1.91% | 22.57B | 378,617,130 |
TONCOIN | Wrapped TON Coin | 5.61 | -0.305636 | -5.17% | 19.41B | 129,435,595 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions